Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 3027 Townsgate Road, Suite 300 WESTLAKE VILLAGE CA 91361 |
Tel: | N/A |
Website: | https://arcutis.com |
IR: | See website |
Key People | ||
Todd Franklin Watanabe President, Chief Executive Officer, Director | Patricia A. Turney Senior Vice President - Operations | David W. Osborne Co-Founder, Senior Vice President, Chief Technology Officer |
David Topper Chief Financial Officer | Todd Tucker Chief Human Resource Officer, Senior Vice President | Masaru Matsuda Senior Vice President, General Counsel |
Ayisha Jeter Senior Vice President - Marketing and Market Access | Patrick E. Burnett Senior Vice President and Chief Medical Officer | Kenneth A. Lock Senior Vice President and Chief Commercial Officer | Matthew R. Moore Senior Vice President, Chief Business Officer |
Business Overview |
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company's pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata. |
Financial Overview |
For the fiscal year ended 31 December 2023, Arcutis Biotherapeutics Inc revenues increased from $3.7M to $59.6M. Net loss decreased 16% to $262.1M. Revenues reflect Product revenue, net increase from $3.7M to $29.2M. Lower net loss reflects Research and development - Balancing val decrease of 44% to $95M (expense), Other income (expense), net increase from $5.8M to $11.8M (income). |
Employees: | 296 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,016M as of Dec 31, 2023 |
Annual revenue (TTM): | $59.61M as of Dec 31, 2023 |
EBITDA (TTM): | -$239.55M as of Dec 31, 2023 |
Net annual income (TTM): | -$262.14M as of Dec 31, 2023 |
Free cash flow (TTM): | -$247.49M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 114,945,238 as of Mar 4, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |